Cells · 2020 · 12 citations · 39 references
Life SciencesNeurobiologyNeurologyClinical ImmunologyImmunopathologyNeuroimmunologyB-cell ResponsesCerebrospinal Fluid BiomarkersDemyelinating DiseasesHumoral ImmunityMultiple SclerosisNeuroinflammationB Cell-mediated NeuroimmunityCerebrospinal Fluid ImmunophenotypingMultiple Sclerosis ImmunopathogenesisMultiple Sclerosis ImmunopathologyNeuroaxonal DamageNeuroaxonal Injury BiomarkersNeuroinflammation In Multiple SclerosisVaricella-zoster Virus Infections
The MRZ reaction (MRZR) comprises the three antibody indices (AIs) against measles, rubella, and varicella zoster virus, reflecting an intrathecal polyspecific B cell response highly specific for multiple sclerosis (MS). Thus, MRZR can be used to confirm a diagnosis of primary progressive MS (PPMS) but its pathophysiological and wider clinical relevance is unclear. This study aimed to investigate whether PPMS patients with a positive MRZR (MRZR+) differ from those with a negative MRZR (MRZR-) according to cerebrospinal fluid (CSF) biomarkers of B cell activity, neuroaxonal damage or glial activity, and clinical features. (1) Methods: In a multicenter PPMS cohort (n = 81) with known MRZR status, we measured B cell-activating factor (BAFF), chemokine CXC ligand 13 (CXCL-13), soluble B cell maturation antigen (sBCMA), soluble transmembrane activator and CAML interactor (sTACI), and chitinase-3-like protein 1 (CHI3L1) in the CSF with enzyme-linked immunosorbent assays (ELISAs). Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were detected in serum and CSF using single molecule array (SIMOA) technology. (2) Results: MRZR+ patients (45.7% of all PPMS patients) revealed higher levels of NfL in CSF compared to MRZR- patients (54.3%). There were positive correlations between each of sBCMA, sTACI, and intrathecal immunoglobin G (IgG) synthesis. Additionally, NfL concentrations in serum positively correlated with those in CSF and those of GFAP in serum. However, MRZR+ and MRZR- patients did not differ concerning clinical features (e.g., age, disease duration, Expanded Disability Status Scale (EDSS) at diagnosis and follow-up); CSF routine parameters; CSF concentrations of BAFF, CXCL-13, sBCMA, sTACI, CHI3L1, and GFAP; or serum concentrations of GFAP and NfL. (3) Conclusions: In PPMS patients, MRZR positivity might indicate a more pronounced axonal damage. Higher levels of the soluble B cell receptors BCMA and transmembrane activator and CAML interactor (TACI) in CSF are associated with a stronger intrathecal IgG synthesis in PPMS.
39
Rating neurologic impairment in multiple sclerosis
John F. Kurtzke · Neurology · 1983 · 14.9K citations
New Multiple Sclerosis Phenotypic Classification
Fred Lublin · European Neurology · 2014 · 4.3K citations
Defining the clinical course of multiple sclerosis
Fred Lublin, Stephen C. Reingold · Neurology · 1996 · 3.7K citations
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalbán, Stephen L. Hauser, Ludwig Kappos et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text
Life Sciences, Immunology, Neurology +17
Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis
Giulio Disanto, Christian Barro, Pascal Benkert et al. · Annals of Neurology · 2017 · 1.2K citations · Full text